Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day
Open Access
- 1 November 2012
- journal article
- research article
- Published by Elsevier BV in Schizophrenia Research
- Vol. 141 (2-3), 144-152
- https://doi.org/10.1016/j.schres.2012.07.029
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptorsNeuropharmacology, 2011
- Pimavanserin tartrate, a 5-HT2A receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteersSleep Medicine, 2011
- Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled studyProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2008
- Persistent Negative Symptoms in Schizophrenia: An OverviewSchizophrenia Bulletin, 2007
- Striatal Vs Extrastriatal Dopamine D2 Receptors in Antipsychotic Response—A Double-Blind PET Study in SchizophreniaNeuropsychopharmacology, 2006
- A Double-Blind Controlled Study of Adjunctive Treatment With Risperidone in Schizophrenic Patients Partially Responsive to ClozapineBritish Journal of Psychology, 2005
- Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairmentInternational Journal of Geriatric Psychiatry, 1998
- The pharmacology and distribution of human 5‐hydroxytryptamine2B (5‐HT2b) receptor gene products: comparison with 5‐HT2a and 5‐HT2c receptorsBritish Journal of Pharmacology, 1995
- A depression rating scale for schizophrenicsSchizophrenia Research, 1990
- A Rating Scale for Drug-Induced AkathisiaThe British Journal of Psychiatry, 1989